Comparative study of intravenous azithromycin alone or intravenous and oral azithromycin for the treatment of pelvic inflammatory disease caused by Chlamydia trachomatis;Komparativno ispitivanje djelotvornosti i podnošljivosti intravenoznog azitromicina i intravenoznog i oralnog azitromicina u liječenju upalne bolesti male zdjelice uzrokovane klamidijom trahomatis

Infektoloski Glasnik

Volumn 23, Issue 3, 2003, Pages 125-128

  Škerk, Višnja ^a   Puntarić, Alemka ^a   Begovac, Josip ^a   Jakšić, Jerko ^b   Strapač, Zvonimir ^b   Vicković, Ninoslava ^a   Vince, Adriana ^a   Desnica, Boško ^a   Škerk, Vedrana ^c   Škalko, Davorin ^a  

^a Croatia   (Croatia)

^b PLIVA CROATIA LTD   (Croatia)

^c UNIVERSITY OF ZAGREB   (Croatia)

Author keywords

Azithromycin; Chlamydia trachomatis; Pelvic inflammatory disease

Indexed keywords

AZITHROMYCIN;

ADULT; ARTICLE; CHLAMYDIA TRACHOMATIS; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DNA RNA HYBRIDIZATION; DRUG EFFICACY; DRUG TOLERABILITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PELVIC INFLAMMATORY DISEASE; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STATISTICAL SIGNIFICANCE; UTERINE ENDOCERVIX;

EID: 11144354961     PISSN: 13312820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (17)

1. Jones RB, Batteiger BE. Chlamydia trachomatis (Trachoma, Perinatal Infection, Lymphogranuloma Venerum and Other Genital Infection). In: Mandell GL, Bennett JE, Dolin R, ur. Principles and Practice of Infectious Diseases. Philadelphia, Churchill Livingstone, 2000; pp 1989-2004.
2. Weidner W, Diemer Th, Huwe P, et al. The role of Chlamydia trachomatis in prostatitis. Int J Antimicrob Agents 2002;19:466-470.
3. Black CH, Byrne G, Carlin E, et al. Chlamydia trachomatis genital infections and single dose azithromycin therapy. Rev Contemp Pharmacother 2000;11:139-256.
4. Paavonen J, Eggert-Kruse W. Chlamydia trachomatis: impaction human. Human Reproduction Update 1999;5:433-447.
5. Paavonen J: Pelvic inflammatory disease. From diagnosis to prevention. Dermatol Clin 1998;16:747-756.
6. Alvarez-Elcoro S, Enzler MJ. The macrolides: Erythromycin, clarithromycin and azithromycin. Mayo Clinic Proceedings 1999;74:613-34.
7. Samra Z, Rosenberg S, Soffer Y, Dan M. In vitro susceptibility of recent clinical isolates of Chlamydia trachomatis to macrolides and tetracyclines. Diagn Microbiol Infect Dis 2001;39:177-179.
8. Foulds G, Shepard RM, Johnson RB. The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 1990;25(Suppl A).73-82.
9. Raulston JE. Pharmacokinetics of azithromycin and erythromycin in human endometrial epithelial cells and in cells infected with Chlamydia trachomatis. J Antimicrob Chemother 1994;34:765-776.
10. Paul TR, Knight ST, Raulston JE, Wyrick PB. Delivery of azithromycin to Chlamydia trachomatis - infected polarized human endometrial epithelial cells by polymorphonnuuclear leucocytes. J Antimicrob Chemother 1997;39:623-630.
11. Amsten GW, Nafziger AN, Foulds G. Pharmacokinetics in serum and leukocyte exposures of oral azithromycin, 1,500 milligrams, given over 3- or 5-day period in healthy subjects. Antimicrob Agents Chemother 1999;43:163-165.
12. Uputa o korištenju lijeka
13. Škerk V, Schoenwald S, Strapač Z, et al. Duration of clinical symptoms in female patients with acute urethral syndrome caused by Chlamydia trachomatis treated with azithromycin or doxycycline. J Chemother 2001;13:176-181.
14. Škerk V, Schoenwald S, Krhen I, i drugi. Azithromycin in the treatment of chronic prostatitis caused by Chlamydia trachomatis. J Chemother 2001;13:664-5.
15. Škerk V, Schoenwald S, Baršić B, et al. Chlamydia trachomatis in urogenital infections. Pharmaca 1999;37:75-86.
16. Bevan DC, Ridgway LG, Rothermel DC. An open label, comparative study of intravenous and oral azithromycin alone, or metronidasole vs. doxycycline + cefoxitim + met + probenecid for the treatment of PID. In: Program and Abstract Book, ICMAS-KO 5.2000; Abstract No, 05.33
17. Bevan CD, Ridgway GL, Rothermel CD. Efficacy and safety of azithromycin as monotherapy or combined with metronidazole compared with two standard multidrug regimens for the treatment of acute pelvic inflammatory disease. J International Medical Research 2003;31:45-54.